Abatacept has 19 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 14 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Infliximab, Infliximab-Axxq, Infliximab-Dyyb. Patients taking Abatacept should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 19
- Contraindicated
- 3
- Major
- 14
Contraindicated (3)
- Abatacept + Infliximab— Combination with TNF blockers including infliximab is not recommended due to increased risk of serious infections with n…
- Abatacept + Infliximab-Axxq— Combination with TNF blockers increased risk of serious infections with no added clinical benefit. Not recommended due t…
- Abatacept + Infliximab-Dyyb— Combination with abatacept is not recommended due to increased risk of serious infections with no added clinical benefit…
Major (14)
- Abatacept + Adalimumab— Increased risk of serious infection when combined with TNF blockers; not recommended in RA patients.
- Abatacept + Adalimumab-Aacf— Increased risk of serious infection when combined with ADALIMUMAB-AACF. Concomitant use is not recommended in patients w…
- Abatacept + Adalimumab-Aaty— Increased risk of serious infection with no added benefit. Concomitant use not recommended in patients with RA.
- Abatacept + Adalimumab-Adaz— Increased risk of serious infection when combined with adalimumab-adaz. Use not recommended in patients with RA due to n…
- Abatacept + Adalimumab-Adbm— Increased risk of serious infection when combined with adalimumab-adbm. Concomitant use not recommended in patients with…
- Abatacept + Adalimumab-Afzb— Increased risk of serious infection when combined with TNF blockers. Use not recommended in patients with RA due to no a…
- Abatacept + Adalimumab-Aqvh— Increased risk of serious infection when combined with YUSIMRY; concomitant use not recommended in RA patients.
- Abatacept + Adalimumab-Atto— Increased risk of serious infection when combined with AMJEVITA (adalimumab-atto). Concomitant use not recommended in RA…
- Abatacept + Adalimumab-Bwwd— Increased risk of serious infection when combined with HADLIMA; not recommended for RA patients.
- Abatacept + Adalimumab-Fkjp— Increased risk of serious infection when combined with adalimumab-fkjp; combination not recommended in RA patients.
- Abatacept + Adalimumab-Ryvk— Increased risk of serious infection when combined with adalimumab-ryvk. Not recommended in patients with RA.
- Abatacept + Certolizumab Pegol— Increased risk of serious infections when used in combination with TNF-blocking agents. Combination therapy not recommen…
- Abatacept + Etanercept— Concomitant administration associated with increased risk of serious infections and no significant additional efficacy. …
- Abatacept + Golimumab— Increased risk of serious infection when used concomitantly with golimumab. Combination not recommended.